Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The Back to Top element was removed, which is a minor UI change with no impact on core information.SummaryDifference0.2%
- Check10 days agoChange DetectedThe page has been updated to include information on Melanoma under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference0.4%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as various new categories related to blood proteins and immunology. However, several specific genetic disease resources and terms have been removed.SummaryDifference3%
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.